Across obesity medicine clinics worldwide, a pattern keeps repeating itself. A patient starts tirzepatide or semaglutide, loses weight in the first few months, and then either plateaus earlier than expected, loses disproportionate amounts of muscle alongside fat, or regains weight rapidly once the medication is paused. They come back frustrated, wondering why the medication "worked for others but not for them." In almost every case, the medication is not the problem. The prog